24/7 Market News Snapshot 22 Jul 2024 – MIRA Pharmaceuticals, Inc. Common Stock (NASDAQ: MIRA)

July 22, 2024 8:45

Press Release

DENVER, Colo., 22 July, 2024 (247marketnews.com) – (Nasdaq:MIRA) are discussed in this article.
MIRA Pharmaceuticals, Inc. has captured attention with a significant 171.34% surge in its Common Stock, reflecting robust investor interest and bullish momentum. The stock, opening at $0.711 and peaking at $1.060, witnessed substantial trading volume of 48.2M, indicative of an upward trend in response to notable market activity. However, traders are advised to exercise caution due to the associated heightened risk that rapid price fluctuations may entail. Analysts suggest vigilance in monitoring potential retracements or consolidation patterns to gauge future movements for MIRA.

In a parallel development, MIRA Pharmaceuticals, Inc. disclosed groundbreaking preclinical data on Ketamir-2, an innovative oral ketamine analog with promising implications for neurological and neuropsychiatric disorders. The Company’s recent preclinical study outcomes demonstrate potential advancements in the treatment landscape for conditions like depression, treatment-resistant depression (TRD), and post-traumatic stress disorder (PTSD).

With a focus on circumventing barriers to brain penetration, Ketamir-2’s unique ability to bypass P-glycoprotein (P-gp) sets it apart, offering enhanced oral absorption and improved access across the blood-brain barrier compared to conventional ketamine formulations. This breakthrough underscores MIRA’s commitment to pushing boundaries in therapeutic innovation, culminating in imminent plans to submit an Investigational New Drug (IND) application to the FDA by year-end, marking a crucial step towards human trials and further validating the potential of Ketamir-2.

Erez Aminov, MIRA Pharmaceuticals’ Chairman & CEO, emphasized the Company’s dedication to reshaping treatment paradigms for neurological and neuropsychiatric disorders. Dr. Itzchak Angel, the Chief Scientific Advisor, lauded Ketamir-2’s transformative promise in mental health treatment, underscoring MIRA’s unwavering pursuit of pioneering solutions.

As MIRA forges ahead with its pioneering research and commitment to elevating patient outcomes, its strides in advancing therapeutic possibilities position the Company at the forefront of innovation in the pharmaceutical landscape.

For additional insights on MIRA Pharmaceuticals, please visit www.mirapharmaceuticals.com.

###

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 Market News, Inc Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.